Gary Vanasse, M.D.
Gary Vanasse, M.D., is Obsidian’s Chief Medical Officer. Dr. Vanasse brings with him over two decades of experience in leading clinical and translational research efforts in oncology and hematology and has served as program head of globally recognized research institutions. Alongside spearheading pathbreaking clinical research in academia as is documented by nearly 30 peer-reviewed publications, Dr. Vanasse has over eight years of experience in the biotech industry-leading cutting edge research teams to deliver effective therapeutics. He was most recently an Executive Director and the Hematology Therapeutic Area Head of Translational Clinical Oncology at the Novartis Institutes of Biomedical Research. Dr. Vanasse had been with Novartis since 2012, helping shape the company’s oncology endeavors. Prior to joining Novartis, Dr. Vanasse was Assistant Professor of Medicine at Yale Medical School and Brigham and Women’s Hospital, Harvard Medical School. Alongside his clinical and research responsibilities, he also served on the Internal Medicine Internship Committee and the Translational Research Committee of Yale Medical School, Dana Farber Cancer Institute’s Hematology – Oncology Fellowship Selection Committee, and was an active member of the Harvard Stem Cell Institute. He is also the recipient of the prestigious American Society of Hematology Fellow Scholar Award. Dr. Vanasse holds a B.S. in biology from Boston College, an M.D. from Georgetown University School of Medicine, and completed his oncology fellowship at the University of Washington-Fred Hutchinson Cancer Research Center.